文献速递乳房整形与再造

乳房再造中Style 410解剖型假体管理的患者决策

Patient Decision-Making for Management of Style 410 Anatomical Implants in Breast Reconstruction.
PubMed 文献 · Plast Reconstr Surg · 2022-11-19

单机构回顾性图表回顾纳入2013至2017年接受Style 410解剖型假体的89例患者,2019年7至9月就FDA召回联系患者并讨论取出/更换与监测。71.9%患者以BIA-ALCL为主要决策因素,22.5%行取出,77.5%选择监测,乳腺癌病史与取出显著相关(P=0.0335)。

要点

  • 89例患者147只再造乳房中,58.5%为肿瘤切除术,41.5%为预防性。
  • 71.9%患者将BIA-ALCL作为管理决策的主要影响因素。
  • 22.5%患者取出Style 410假体,77.5%选择监测;乳腺癌病史与取出显著相关(P=0.0335)。

核心结论

  • 多数携带Style 410毛面假体的患者选择对BIA-ALCL进行监测。
  • 在决定取出或更换Style 410假体时,整形外科医生应与患者共同仔细列明管理选项。

研究设计与样本

  • 单机构回顾性图表回顾,纳入两名外科医生处接受410解剖型假体的所有患者。
  • 2019年7月至9月就FDA召回联系患者,并请其预约咨询讨论取出/更换与监测。
  • 2013年至2017年共89例患者接受410假体,再造乳房147只。

主要发现

  • 147只再造乳房中58.5%为肿瘤切除术,41.5%为预防性。
  • 71.9%患者将BIA-ALCL作为管理决策的主要影响因素,其他因素包括外观、与BIA-ALCL无关的假体顾虑及其他医疗状况。
  • 20例患者(22.5%)行Style 410假体取出,其余77.5%选择监测。
  • 乳腺癌病史与Style 410假体取出存在显著关联(P=0.0335)。

关键数值与推荐

  • 71.9%患者以BIA-ALCL为主要决策影响因素。
  • 22.5%患者行取出,77.5%选择监测。
  • 乳腺癌病史与取出显著相关(P=0.0335)。

临床怎么用

  • 原文结论指出,在决定取出或更换Style 410假体时,整形外科医生应与患者共同仔细列明管理选项。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In July of 2019, the U.S. Food and Drug Administration (FDA) recalled the Allergan Natrelle 410 Highly Cohesive Anatomically Shaped Silicone-Filled Textured Breast Implants because of a heightened risk of developing breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). The objective of this study was to describe patient decision-making in management of preexisting 410 textured implants. METHODS: A single-institution retrospective chart review was conducted to determine all patients who received 410 anatomical implants from two surgeons. Patients who received these implants were contacted in July to September of 2019 regarding the FDA recall and asked to schedule a consultation to discuss explant/exchange versus surveillance. Outcomes analyzed included decision of surveillance versus explantation and subsequent reconstructive operations. RESULTS: Eighty-nine patients had received 410 implants from 2013 to 2017. Of the 147 breasts that were reconstructed, 58.5% were oncologic mastectomies and 41.5% were prophylactic. The majority of patients (71.9%) cited BIA-ALCL as the predominant influencing factor in their decision for management. Other factors included appearance, implant concerns unrelated to BIA-ALCL, and other medical conditions. Twenty patients (22.5%) underwent explantation of the Style 410 implants. The remaining 77.5% of patients elected for monitored surveillance. There was a significant association between a history of breast cancer and explantation of the Style 410 implants ( P = 0.0335). CONCLUSIONS: The majority of patients with Style 410 textured implants elected to undergo surveillance for BIA-ALCL. When deciding to explant or exchange the Style 410 implants, plastic surgeons should work in conjunction with their patients to carefully outline management options.

来源:Plast Reconstr Surg,查看原文。版权归原作者所有。

引用

  1. Boyd CJ, Salibian AA, Bekisz JM, et al. Patient Decision-Making for Management of Style 410 Anatomical Implants in Breast Reconstruction. Plast Reconstr Surg. 2022. PMID: 36730538. doi:10.1097/PRS.0000000000009901

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。